Print this page    •   Back to Web version of article

Medical News
Efavirenz May Still Be Effective at Lower Dose, Research Suggests

July 8, 2013

Australian researchers from the Kirby Institute at the University of New South Wales (UNSW) presented findings at the International AIDS Society Conference in Kuala Lumpur, Malaysia, showing that a lower dose of an HIV drug was effective in keeping the virus suppressed. The investigators followed 630 HIV-positive individuals from 13 countries in Africa, Asia, Australia, Europe, and Latin America for a year. Half of the study participants took one-third less of the antiretroviral drug efavirenz and the other half took a standard dose of the drug. The study results found that taking one-third less of the drug adequately suppressed the virus without any side effects. According to Sean Emery, UNSW professor, protocol chairperson of the study, and head of the therapeutic and vaccine research program at the Kirby Institute, the study findings have the potential to affect the treatment of millions of HIV positive people -- more individuals could receive treatment for the same amount of funding.

Back to other news for July 2013

Excerpted from:
Digital Journal
07.05.2013; Kathleen Blanchard




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/72099/landmark-finding-could-mean-lifesaving-hiv-therapy.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.